Advaxis reports 'encouraging' PhII cervical cancer vaccine data

An article from FierceVaccines
September 18, 2015
Operating in a field that can leave patients with few options, Advaxis ($ADXS) rolled out data for its cervical cancer vaccine this week that represent a "meaningful step" for those afflicted, according to one expert.
In the first stage of a Phase II study of axalimogene filolisbac (ADXS-HPV), Princeton, NJ-based Advaxis said 38.5% of patients who previously failed at least one line of therapy were alive after 12 months; each was given an an estimated four to 7 months to live. However, as noted in Advaxis' release, in 17 previous studies of investigational agents conducted by the Gynecologic Oncology Group, the 12-month survival rate has never been above 30%
Advaxis CEO Daniel O'Connor said in a statement that the data represent "some of the most encouraging Phase 2 data to date in metastatic cervical cancer," while presenter Dr. Tom Herzog said the results "are a meaningful step forward in meeting the needs of women who require second-line treatment for PRmCC." Despite the enthusiasm, the biotech's shares were down about 11% one day following the announcement.
Read the full article here.
Common Disease Taxonomy: 
Common Vaccine Taxonomy: